Abstract
Lung cancer remains the leading cause of cancer mortality globally, with approximately 2.48 million new cases and 1.8 million deaths in 202222. Despite declining age-standardized incidence rates (ASIR) in high-income countries, absolute burden continues rising due to population aging and persistent tobacco use in lower-income regions. This review synthesizes registry-based and model-based data on global and regional epidemiology from 2016 to Q1 2026, highlighting divergent sex-specific trends, histological shifts toward adenocarcinoma, attributable risk factors, mortality and disability-adjusted life year (DALY) patterns, and the impact of screening and tobacco control policies.
Data Sources and Methods
This review integrates data from the Global Burden of Disease (GBD) Study 2017 and 2021191013, IARC/GLOBOCAN22, WHO Mortality Database25, U.S. SEER program26, and population-based registries from Asia, Europe, and Oceania234. The GBD employs Bayesian hierarchical modeling with age-standardization to the GBD standard population; DALY comprises years of life lost (YLL) and years lived with disability (YLD) using standard life tables and disability weights. Joinpoint regression identifies temporal inflection points and annual percent change (APC) with 95% confidence intervals. Incidence and mortality are reported as age-standardized rates per 100,000. Limitations include underascertainment in low-resource settings, temporal lags (GBD 2021 extends through 2021; projections to 2026 require extrapolation), inter-registry coding variability, and incomplete histological classification in some databases.
Incidence and Prevalence: Global and Regional Patterns
Overall Burden and Regional Variation
In 2022, global lung cancer incidence reached approximately 2.48 million cases with substantial regional heterogeneity22. Among adults aged ≥55 years in 2021, the GBD 2021 estimated 2,021,521 incident cases (ASIR 167.36 per 100,000) and a prevalence reflecting cumulative 5-year survivors13. East Asia bore the highest incidence (836,971 cases; ASIR 271.83 per 100,000), followed by high-sociodemographic-index (SDI) regions in North America and Europe (ASIR ~226 per 100,000)13. In contrast, low-SDI countries—predominantly Sub-Saharan Africa—reported markedly lower ASIR (31.31 per 100,000), reflecting lower smoking prevalence, younger population structures, and potentially under-registration13.
U.S. data from SEER (2018–2022) documented an overall ASIR of 47.8 per 100,000, with males at 53.1 and females at 43.9 per 100,00026. In Japan (Osaka registry, 1975–2008), incidence increased modestly in both sexes (males +0.3% APC, females +1.1% APC) despite mortality declines, indicating improving survival3.
Sex Disparities
Pronounced sex differences persist globally: male ASIR (243.99 per 100,000) exceeded female rates (104.81 per 100,000) by more than twofold13. Historical analyses (1973–2007) documented divergent trends—males in 13 of 18 developed populations showed declining ASIR (AAPC −0.7% to −2.9%), while females exhibited rising incidence (AAPC +1.3% to +5.0%)2. This gender divergence reflects cohort effects from delayed female smoking uptake and differential cessation patterns.
Histological Distribution and Stage at Diagnosis
Histological shifts are evident across registries. Adenocarcinoma now predominates, particularly in never-smokers and Asian populations, while squamous cell carcinoma (SCC) and small cell carcinoma (SMC) decline in parallel with reduced smoking prevalence3. In Osaka, adenocarcinoma incidence increased across all age groups in both sexes, whereas SCC and SMC declined significantly3. Adenocarcinoma accounts for the majority of lung cancer in never-smokers and exhibits higher frequencies of targetable driver mutations16.
U.S. SEER data indicate that 52% of cases present with distant metastatic disease, 21% with regional spread, and only 23% localized at diagnosis26, underscoring the need for earlier detection strategies.
Temporal Trends Over the Past Decade (2016–2026)
Incidence Trends
From 1990 to 2017, global age-standardized incidence increased modestly by 3.0% (26.3 to 27.1 per 100,000), but absolute cases doubled due to population growth1. Recent analyses through 2021 show continued increases in absolute burden, with projections to 2050 estimating 4.62 million cases and 3.55 million deaths if current trends persist22.
Regional heterogeneity is striking: high-SDI countries demonstrate declining incidence (Australia AAPC −0.56%, Canada −0.81%), while middle-SDI nations show increases (AAPC +0.3%)113. Croatia exhibited overall declining incidence (AAPC −1.3%), with males declining (−2.2%) but females increasing (+1.4%)4. Joinpoint analyses identified inflection points in 1994 (shift to declining DALY rates) and 2009 (slowing of decline)1, corresponding to maturation of tobacco control policies.
Mortality Trends
Age-standardized mortality rates (ASMR) declined globally by 7% from 1990 to 2017 (25.5 to 23.7 per 100,000)1. U.S. data show accelerated mortality decline at −4.2% annually (2014–2023)26. In China, however, standardized mortality increased from 36.04 to 40.41 per 100,000 (1990–2013), reflecting rising smoking-attributable burden (net drift +0.72% per year for smoking-related deaths), contrasting sharply with U.S. declines (−3.03% per year)527.
High-SDI regions demonstrated the steepest ASMR declines (AAPC −1.2%), while middle-SDI countries showed increases (+0.3%)1. For PM₂.₅-attributable lung cancer, high-SDI regions achieved −2.21% annual ASMR decline (1990–2019), whereas low-to-middle SDI regions experienced rising rates23.
Etiology and Risk Factor Attribution
Tobacco Smoking
Tobacco remains the dominant risk factor. In 2021, smoking caused approximately 1,238,650 lung cancer deaths globally (1,195,800 from active smoking, 97,910 from secondhand smoke)9. Australian cohort data quantified population attributable fractions (PAF): smoking cessation could prevent 53.7% (95% CI: 50.0–57.2%) of lung cancers over 40 years and 18.3% (11.0–25.1%) over 10 years6. Global smoking prevalence in 2022 was 28.5% in males and 5.96% in females, with projections indicating continued decline under current policies but persistence of substantial absolute numbers15.
Secondhand smoke carries a relative risk of 1.28 (95% CI: 1.10–1.48) for lung cancer in non-smokers, as demonstrated in Japanese meta-analyses17. In Spain (2011), secondhand smoke caused 124 lung cancer deaths among never-smokers14.
Environmental and Occupational Exposures
Ambient PM₂.₅ accounted for 374,210 deaths and 8,934,120 DALYs in 2021 globally, with Southeast Asia, East Asia, and Oceania bearing the highest burden (ASMR 8.81 per 100,000)9. East Asia contributed >50% of global PM₂.₅-attributable lung cancer burden in 201923. Household air pollution from solid fuels exposed 2.67 billion people (33.8% of global population) in 2021, causing 111 million DALYs (age-standardized DALY rate 1,500.3 per 100,000), with the highest burden in Sub-Saharan Africa (4,044.1 per 100,000) and South Asia (3,213.5 per 100,000)10.
Radon is the leading risk factor for lung cancer in never-smokers, with an adjusted excess relative risk of 0.15 per 100 Bq/m³ (95% CI: 0.06–0.25), though with pronounced sex differences (men 0.46, women 0.09 per 100 Bq/m³)8. Occupational diesel motor exhaust exposure showed an odds ratio of 1.66 (95% CI: 1.08–2.56) for ≥34 years of exposure, with elevated risk for squamous cell carcinoma (OR 1.73)21. No multiplicative interactions between occupational carcinogens (asbestos, silica, diesel) and tobacco smoking were identified20.
Lung Cancer in Never-Smokers
An estimated 17,000–26,000 annual U.S. lung cancer deaths occur in never-smokers, ranking as the seventh leading cause of cancer mortality16. Adenocarcinoma predominates, with higher frequencies of targetable driver mutations. In a multi-cohort study of 91,588 never-smokers, only age (HR 2.45 per 10 years), male sex (HR 2.25), and paradoxically high fruit/vegetable intake (HR 2.29) showed associations; conventional risk factors captured at baseline did not predict risk, highlighting unmeasured genetic and environmental determinants19.
Mortality, Survival, and Disability-Adjusted Life Years
Survival Trends
U.S. 5-year relative survival improved from ~14% in the mid-1990s to 28.1% (2015–2021)26, reflecting advances in staging, surgical techniques, targeted therapies, and immunotherapy. Stage-specific survival remains highly disparate: localized disease (23% of cases) achieves 64.7% 5-year survival, regional disease (21% of cases) 37.1%, and distant disease (52% of cases) only 9.7%26. Despite these gains, lung cancer continues to account for 20.2% of all U.S. cancer deaths26.
DALY Decomposition
Global age-standardized DALY rates declined 15.3% from 1990 to 2017 (594.0 to 503.1 per 100,000)1. In 2021, adults ≥55 years accounted for 37,632,985 DALYs globally (ASDR 2,892.52 per 100,000)13. YLL comprises >98% of DALYs, with YLD increasing 113.9% in absolute terms but only 9.8% after age-standardization, remaining <2% of total burden1. This composition shift reflects improved survival (more patients living with disease) and treatment-related morbidity.
Regional disparities are profound: high-SDI countries showed steeper DALY decline (AAPC −1.2%) than middle-SDI nations (+0.3%)1. In China, the standardized DALY rate decreased from 813.64 to 792.22 per 100,000 (1990–2013), with YLL declining but YLD rising 29.87%, indicating growing morbidity burden despite mortality plateau27.
Economic Burden
Projections to 2050 indicate escalating absolute burden, with lung cancer cases potentially reaching 4.62 million and deaths 3.55 million globally, imposing substantial direct medical costs and productivity losses22. Detailed economic estimates by region for 2016–2026 were not captured in the retrieved materials.
Disparities and Policy Context
Socioeconomic and Racial/Ethnic Disparities
U.S. data reveal pronounced disparities: non-Hispanic Black males exhibit the highest incidence (65.2 per 100,000) and mortality (44.5 per 100,000)26. The smoking-attributable burden is highest in males, those with lower educational attainment, unmarried individuals, and those in remote areas6. Globally, concentration index analysis showed that lung cancer burden shifted from higher-SDI to lower-SDI regions for PM₂.₅-attributable disease (CI: 0.05 to −0.10), while tobacco-attributable burden persisted in higher-SDI countries (CI: 0.34 to 0.25)9.
Screening and Tobacco Control Policies
Low-dose CT (LDCT) screening uptake varies widely by region; detailed 2016–2026 uptake data were limited in the retrieved materials. Tobacco control policies—taxation, smoke-free laws, cessation programs—correlate with declining ASMR in high-income countries. Modeling indicates that achieving 5% smoking prevalence by 2050 could avoid 735 million male YLLs and increase life expectancy to 77.1 years for males and 80.8 years for females15. Air quality regulations in high-SDI regions contributed to declining PM₂.₅-attributable mortality (−2.21% annually)23.
Limitations
Key limitations include: (1) temporal lags—GBD 2021 and most registries extend only through 2021, requiring extrapolation for 2022–2026; (2) underascertainment in low-resource settings, particularly Sub-Saharan Africa and parts of South Asia; (3) incomplete histological and stage classification in many registries; (4) model-based estimates rely on Bayesian assumptions and may differ from registry-based data; (5) PAF estimates for genetic susceptibility, COPD, and pulmonary fibrosis were not quantified in the retrieved 2016–2026 literature; and (6) economic burden and quality-of-life data remain sparse for many regions.
Conclusion
Global lung cancer epidemiology from 2016 to Q1 2026 reveals a paradox: age-standardized incidence and mortality are declining in high-income countries due to tobacco control and therapeutic advances, yet absolute burden continues rising due to population aging, with projections reaching 4.62 million cases by 2050. Divergent sex-specific trends—declining in males, stable or rising in females—signal a shifting epidemic. Histological shifts toward adenocarcinoma underscore evolving etiology, with rising burden in never-smokers demanding investigation of genetic and environmental determinants beyond tobacco. Risk attribution remains dominated by smoking (53.7% PAF), with PM₂.₅ (374,210 deaths in 2021) and household air pollution (111 million DALYs) contributing substantially in lower-income regions. Improving 5-year survival to 28.1% in the U.S. reflects therapeutic progress, though late-stage diagnosis remains predominant globally. Strengthened surveillance, targeted tobacco control, air quality regulation, expanded LDCT screening, and equitable access to precision therapies are essential to curb future burden and address persistent disparities.